|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wilson MA and Schuchter LM: Chemotherapy
for Melanoma. Cancer Treat Res. 167:209–229. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A,
Borresen-Dale AL, et al: Signatures of mutational processes in
human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colombino M, Capone M, Lissia A, Cossu A,
Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, et
al: BRAF/NRAS mutation frequencies among primary tumors and
metastases in patients with melanoma. J Clin Oncol. 30:2522–2529.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luebker SA and Koepsell SA: Diverse
mechanisms of BRAF inhibitor resistance in melanoma identified in
clinical and preclinical studies. Front Oncol. 9:2682019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sosman JA, Kim KB, Schuchter L, Gonzalez
R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ,
Flaherty KT, et al: Survival in BRAF V600-mutant advanced melanoma
treated with vemurafenib. N Engl J Med. 366:707–714. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Long GV, Stroyakovskiy D, Gogas H,
Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A,
Grob JJ, et al: Combined BRAF and MEK inhibition versus BRAF
inhibition alone in melanoma. N Engl J Med. 371:1877–1888. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Flaherty KT, Infante JR, Daud A, Gonzalez
R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N,
et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600
mutations. N Engl J Med. 367:1694–1703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WJ Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robert C, Karaszewska B, Schachter J,
Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R,
Grange F, Mortier L, et al: Improved overall survival in melanoma
with combined dabrafenib and trametinib. N Engl J Med. 372:30–39.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Khan M, Maryam A, Qazi JI and Ma T:
Targeting apoptosis and multiple signaling pathways with Icariside
II in cancer cells. Int J Biol Sci. 11:1100–1112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song J, Shu L, Zhang Z, Tan X, Sun E, Jin
X, Chen Y and Jia X: Reactive oxygen species-mediated mitochondrial
pathway is involved in Baohuoside I-induced apoptosis in human
non-small cell lung cancer. Chem Biol Interact. 199:9–17. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu J, Zuo F, Du J, Wong PF, Qin H and Xu
J: Icariside II induces apoptosis via inhibition of the EGFR
pathways in A431 human epidermoid carcinoma cells. Mol Med Rep.
8:597–602. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu J, Guan M, Wong PF, Yu H, Dong J and Xu
J: Icariside II potentiates paclitaxel-induced apoptosis in human
melanoma A375 cells by inhibiting TLR4 signaling pathway. Food Chem
Toxicol. 50:3019–3024. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Du J, Wu J, Fu X, Tse AK, Li T, Su T and
Yu ZL: Icariside II overcomes TRAIL resistance of melanoma cells
through ROS-mediated downregulation of STAT3/cFLIP signaling.
Oncotarget. 7:52218–52229. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nazarian R, Shi H, Wang Q, Kong X, Koya
RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al: Melanomas
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS
upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen G, Yang Y, Xu C and Gao S: A Flow
Cytometry-based Assay for measuring mitochondrial membrane
potential in cardiac myocytes after hypoxia/reoxygenation. J Vis
Exp. 2018.
|
|
19
|
Feng JH, Nakagawa-Goto K, Lee KH and Shyur
LF: A Novel plant sesquiterpene lactone derivative, DETD-35,
suppresses BRAFV600E mutant melanoma growth and overcomes acquired
vemurafenib resistance in mice. Mol Cancer Ther. 15:1163–1176.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Westphal D, Kluck RM and Dewson G:
Building blocks of the apoptotic pore: How Bax and Bak are
activated and oligomerize during apoptosis. Cell Death Differ.
21:196–205. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vaseva AV and Moll UM: The mitochondrial
p53 pathway. Biochim Biophys Acta. 1787:414–420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vergani E, Vallacchi V, Frigerio S, Deho
P, Mondellini P, Perego P, Cassinelli G, Lanzi C, Testi MA,
Rivoltini L, et al: Identification of MET and SRC activation in
melanoma cell lines showing primary resistance to PLX4032.
Neoplasia. 13:1132–1142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aida S, Sonobe Y, Tanimura H, Oikawa N,
Yuhki M, Sakamoto H and Mizuno T: MITF suppression improves the
sensitivity of melanoma cells to a BRAF inhibitor. Cancer Lett.
409:116–124. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Filitis DC, Rauh J and Mahalingam M: The
HGF-cMET signaling pathway in conferring stromal-induced
BRAF-inhibitor resistance in melanoma. Melanoma Res. 25:470–478.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McGill GG, Haq R, Nishimura EK and Fisher
DE: c-Met expression is regulated by Mitf in the melanocyte
lineage. J Biol Chem. 281:10365–10373. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen M, Wu J, Luo Q, Mo S, Lyu Y, Wei Y
and Dong J: The anticancer properties of herba epimedii and its
main bioactive componentsicariin and icariside II. Nutrients.
8(pii): E5632016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mizushima N and Klionsky DJ: Protein
turnover via autophagy: Implications for metabolism. Annu Rev Nutr.
27:19–40. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Das G, Shravage BV and Baehrecke EH:
Regulation and function of autophagy during cell survival and cell
death. Cold Spring Harb Perspect Biol. 4(pii):
a0088132012.PubMed/NCBI
|
|
29
|
Franke JC, Plotz M, Prokop A, Geilen CC,
Schmalz HG and Eberle J: New caspase-independent but ROS-dependent
apoptosis pathways are targeted in melanoma cells by an
iron-containing cytosine analogue. Biochem Pharmacol. 79:575–586.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Quast SA, Berger A and Eberle J:
ROS-dependent phosphorylation of Bax by wortmannin sensitizes
melanoma cells for TRAIL-induced apoptosis. Cell Death Dis.
4:e8392013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Corazao-Rozas P, Guerreschi P, Jendoubi M,
Andre F, Jonneaux A, Scalbert C, Garcon G, Malet-Martino M,
Balayssac S, Rocchi S, et al: Mitochondrial oxidative stress is the
Achille's heel of melanoma cells resistant to Braf-mutant
inhibitor. Oncotarget. 4:1986–1998. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bauer D, Werth F, Nguyen HA, Kiecker F and
Eberle J: Critical role of reactive oxygen species (ROS) for
synergistic enhancement of apoptosis by vemurafenib and the
potassium channel inhibitor TRAM-34 in melanoma cells. Cell Death
Dis. 8:e25942017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hodgkinson CA, Moore KJ, Nakayama A,
Steingrimsson E, Copeland NG, Jenkins NA and Arnheiter H: Mutations
at the mouse microphthalmia locus are associated with defects in a
gene encoding a novel basic-helix-loop-helix-zipper protein. Cell.
74:395–404. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carreira S, Goodall J, Aksan I, La Rocca
SA, Galibert MD, Denat L, Larue L and Goding CR: Mitf cooperates
with Rb1 and activates p21Cip1 expression to regulate cell cycle
progression. Nature. 433:764–769. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Carreira S, Goodall J, Denat L, Rodriguez
M, Nuciforo P, Hoek KS, Testori A, Larue L and Goding CR: Mitf
regulation of Dia1 controls melanoma proliferation and
invasiveness. Genes Dev. 20:3426–3439. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Garraway LA, Widlund HR, Rubin MA, Getz G,
Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J,
et al: Integrative genomic analyses identify MITF as a lineage
survival oncogene amplified in malignant melanoma. Nature.
436:117–122. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Smith MP, Brunton H, Rowling EJ, Ferguson
J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque
MP, et al: Inhibiting Drivers of Non-mutational drug tolerance is a
salvage strategy for targeted melanoma therapy. Cancer Cell.
29:270–284. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Muller J, Krijgsman O, Tsoi J, Robert L,
Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes
Foppen MH, et al: Low MITF/AXL ratio predicts early resistance to
multiple targeted drugs in melanoma. Nat Commun. 5:57122014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Smith MP, Ferguson J, Arozarena I, Hayward
R, Marais R, Chapman A, Hurlstone A and Wellbrock C: Effect of
SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J
Natl Cancer Inst. 105:33–46. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ko GA and Cho SK: Phytol suppresses
melanogenesis through proteasomal degradation of MITF via the
ROS-ERK signaling pathway. Chem Biol Interact. 286:132–140. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu F, Fu Y and Meyskens FJ Jr: MiTF
regulates cellular response to reactive oxygen species through
transcriptional regulation of APE-1/Ref-1. J Invest Dermatol.
129:422–431. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Straussman R, Morikawa T, Shee K,
Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J,
Frederick DT, et al: Tumour micro-environment elicits innate
resistance to RAF inhibitors through HGF secretion. Nature.
487:500–504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Etnyre D, Stone AL, Fong JT, Jacobs RJ,
Uppada SB, Botting GM, Rajanna S, Moravec DN, Shambannagari MR,
Crees Z, et al: Targeting c-Met in melanoma: Mechanism of
resistance and efficacy of novel combinatorial inhibitor therapy.
Cancer Biol Ther. 15:1129–1141. 2014. View Article : Google Scholar : PubMed/NCBI
|
